Villach-based biotech company Efferon has secured €2.5 million in seed funding to scale production of its blood purification technology designed for the treatment of sepsis and septic shock.
The round was backed by private investors from the DACH region. The newly raised capital was used to support the construction of a new EU manufacturing facility for the company’s flagship device, Efferon LPS, and to increase overall production capacity to meet growing international demand.
Scaling Hemoadsorption Technology Across Europe
Founded by Dima Romashin and the Efferon team, the company develops multimodal hemoadsorption devices that remove endotoxins and inflammatory mediators directly from the bloodstream.
Its lead product, Efferon LPS, is designed for patients suffering from sepsis and septic shock, conditions that remain among the leading causes of mortality worldwide.
The company says its expanded manufacturing operations will support annual production capacity of up to 70,000 devices as part of its broader international commercialisation strategy.
According to CEO and co-founder Dima Romashin, the company is now focused on accelerating adoption across Europe while preparing for future expansion into the US market.
“Efferon LPS is already used in more than 40 countries and has generated over €1 million in revenue, proving both the clinical value of the technology and market demand,” Romashin said.
“We are now building the regulatory and distribution infrastructure required to make Efferon a global standard of care for sepsis treatment.”
Advertisement
Advancing Pediatric Sepsis Treatment
The company recently received CE MDR certification for Efferon NEO, a pediatric version of its hemoadsorption technology designed for neonatal and pediatric patients with sepsis and septic shock.
The company says the device became the first hemoadsorption system in Europe approved specifically for pediatric use in these conditions.
The certification was supported by results from the multicenter LASSO NEO study, which demonstrated significant reductions in 28-day mortality rates among treated patients.
According to the study, mortality was reduced to 9% compared to 35% in the control group.
Reducing ICU Costs And Improving Outcomes
The startup states that its technology can also lower hospital treatment costs by accelerating patient stabilisation and reducing time spent in intensive care.
The company says hospitals using the system may reduce ICU-related treatment expenses by up to 40% per patient through shorter stays and reduced dependency on vasopressors and mechanical ventilation.
Dr. Jan Kielstein said the expansion of European manufacturing capacity could improve access to advanced sepsis care across the region.
“Every minute, more than one person in Europe dies from sepsis,” Kielstein said.
“Making these therapies more accessible has the potential to significantly improve intensive care treatment and patient outcomes.”
About Efferon
Efferon develops blood purification technologies designed to remove endotoxins and inflammatory mediators from the bloodstream. Its product portfolio includes Efferon LPS and Efferon NEO, both focused on treating sepsis and septic shock in adult and pediatric patients. The company’s technology is currently used across more than 40 countries worldwide.
